This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Mar;121(2):202-4.

doi: 10.3810/pgm.2009.03.1995.

Review of ONTARGET: treating patients at high risk for vascular events with telmisartan, ramipril, or both. Commentary

Robert M Guthrie¹

Affiliations

PMID: 19332981
DOI: 10.3810/pgm.2009.03.1995

Comment

Review of ONTARGET: treating patients at high risk for vascular events with telmisartan, ramipril, or both. Commentary

Robert M Guthrie. Postgrad Med. 2009 Mar.

. 2009 Mar;121(2):202-4.

doi: 10.3810/pgm.2009.03.1995.

Author

Robert M Guthrie¹

Affiliation

¹ Department of Emergency Medicine, Ohio State University, Columbus, OH 43212, USA. guthrie.1@osu.edu

PMID: 19332981
DOI: 10.3810/pgm.2009.03.1995

No abstract available

PubMed Disclaimer

Comment on

Telmisartan, ramipril, or both in patients at high risk for vascular events.
ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. ONTARGET Investigators, et al. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378520 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Atypon